OS Therapies secured Advanced Therapy Medicinal Product (ATMP) designation for its lead product, OST‑HER2, a Listeria‑based immunotherapy targeting pulmonary recurrence in resected osteosarcoma. The designation was granted during the EMA Committee for Advanced Therapies (CAT) meeting held March 18‑20, 2026 and announced March 25, 2026.
The ATMP status opens the Conditional Marketing Authorisation (CMA) accelerated pathway in the EU, reduces regulatory fees for a small‑to‑medium enterprise, and aligns the product with the EU’s advanced‑therapy framework. It is the European counterpart to the U.S. FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation, signaling that the EMA views OST‑HER2 as a promising advanced therapy and is willing to engage in a tailored regulatory assessment.
OS Therapies plans to file a CMA submission in the coming weeks and will engage with the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the FDA concurrently. CEO Paul Romness said the ATMP designation “marks a significant milestone along OST‑HER2's path toward becoming the standard of care in Europe” and that it “increases the likelihood that we will receive conditional marketing authorisation later this year, which would help us establish a significant revenue stream for the Company projected to begin in 2027.”
For investors, the ATMP milestone removes a key regulatory hurdle and positions OST‑HER2 for earlier market entry in the EU. Conditional approval could generate revenue as early as 2027, potentially offsetting the company’s current liquidity constraints. The designation also enhances the likelihood of a Priority Review Voucher (PRV) under the U.S. Rare Pediatric Disease Designation, which could be monetised for additional capital. The most recent publicly disclosed PRV transaction occurred in February 2026 at a reported value of $205 million, and the PRV program reauthorization extends eligibility to September 30 2029.
OS Therapies has also secured Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designation from the FDA, and Orphan Drug and Fast Track Designations from the EMA. The company’s pipeline focuses on a listeria‑based platform that targets HER2‑expressing osteosarcoma cells, positioning it within a niche but critical oncology space.
The ATMP designation is a material regulatory event that could accelerate the product’s commercial launch, improve the company’s cash‑flow prospects, and provide a new source of capital through a PRV sale. It also signals strong regulatory confidence in the product’s safety and efficacy profile, potentially improving investor perception of the company’s long‑term growth prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.